This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robbins Arroyo LLP Files A Class Action Against Star Scientific, Inc.

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Robbins Arroyo LLP announces that the firm filed a federal securities fraud class action complaint on May 7, 2013, in the U.S. District Court for the Eastern District of Virginia on behalf of all persons who purchased or otherwise acquired Star Scientific stock between October 31, 2011 and March 18, 2013, inclusive (the "Class Period"), against the company and certain of its officers and directors for violations of the Securities Exchange Act of 1934.  Star Scientific and its operating subsidiaries manufacture, distribute, and sell consumer products and dietary supplements.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Star Scientific Accused of Making False and Misleading Statements Concerning the Company's Business and Operations

The complaint alleges that defendants made materially false and misleading statements during the Class Period in press releases, analyst conference calls, and filings with the U.S. Securities and Exchange Commission (the "SEC").  Specifically, the complaint alleges that Star Scientific misled investors about the true nature and extent of Johns Hopkins University's (" Johns Hopkins") involvement in the clinical testing of the company's nutritional supplement, Anatabine; concealed the true nature and extent of its liquidity condition; engaged in improper private placement and related-party transactions since at least 2006; and delayed disclosure of the fact that the company had received subpoenas from the U.S. Attorney's office investigating potential securities fraud.

As a result of defendants' false statements, Star Scientific's stock traded at artificially inflated prices during the Class Period, reaching a high of $4.99 per share on July 3, 2012. 

Star Scientific's Stock Price Drops on News of False Statements and Federal Government Investigation

On January 23, 2013, The Street issued an article entitled "Star Scientific's Made-Up, Misleading Relationship with Johns Hopkins" stating that Star Scientific misled investors concerning Johns Hopkins' involvement in the clinical testing of Anatabine.  On this news, Star Scientific's stock price dropped $0.31 per share to close at $2.33 per share—a one-day decline of nearly 12% on volume of 6.1 million shares.

On March 18, 2013, Star Scientific filed its annual report with the SEC for its fiscal year ended December 31, 2012.  In the annual report, the company disclosed for the first time that it was being investigated by the federal government.  On this news, Star Scientific's stock price dropped another $0.34 per share to close at $1.64 per share—a one-day decline of 17%.

Overall, after these revelations reached the market, Star Scientific's share price declined a total of 67% from the Class Period high.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs